JP2021529539A5 - - Google Patents

Info

Publication number
JP2021529539A5
JP2021529539A5 JP2021500042A JP2021500042A JP2021529539A5 JP 2021529539 A5 JP2021529539 A5 JP 2021529539A5 JP 2021500042 A JP2021500042 A JP 2021500042A JP 2021500042 A JP2021500042 A JP 2021500042A JP 2021529539 A5 JP2021529539 A5 JP 2021529539A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
isolated nucleic
amino acid
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529539A (ja
JP7376564B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040185 external-priority patent/WO2020006568A1/en
Publication of JP2021529539A publication Critical patent/JP2021529539A/ja
Publication of JP2021529539A5 publication Critical patent/JP2021529539A5/ja
Application granted granted Critical
Publication of JP7376564B2 publication Critical patent/JP7376564B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500042A 2018-06-29 2019-07-01 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体 Active JP7376564B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692609P 2018-06-29 2018-06-29
US62/692,609 2018-06-29
PCT/US2019/040185 WO2020006568A1 (en) 2018-06-29 2019-07-01 Cd6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders

Publications (3)

Publication Number Publication Date
JP2021529539A JP2021529539A (ja) 2021-11-04
JP2021529539A5 true JP2021529539A5 (https=) 2022-07-08
JP7376564B2 JP7376564B2 (ja) 2023-11-08

Family

ID=67587926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500042A Active JP7376564B2 (ja) 2018-06-29 2019-07-01 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体

Country Status (7)

Country Link
US (2) US12281151B2 (https=)
EP (2) EP4706679A2 (https=)
JP (1) JP7376564B2 (https=)
CN (2) CN112638478B (https=)
AU (1) AU2019295855B2 (https=)
ES (1) ES3061216T3 (https=)
WO (1) WO2020006568A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
WO2021138454A1 (en) * 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20250161360A1 (en) * 2022-05-10 2025-05-22 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8426467D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
EP3842448A1 (en) 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
LT3535392T (lt) 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers

Similar Documents

Publication Publication Date Title
JP7550591B2 (ja) 多重特異的ＮＫｐ４６結合タンパク質
US20230055445A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
KR102523402B1 (ko) 이중특이적 체크포인트 억제제 항체
JP6971153B2 (ja) 多重特異的ｎｋエンゲイジャータンパク質
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
JP7269167B2 (ja) モジュラー四価二重特異性抗体プラットフォーム
JP2020503015A (ja) 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
CA3169601A1 (en) Bispecific antigen binding molecules targeting ox40 and fap
KR20200085828A (ko) 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
WO2018068182A1 (en) Novel anti-ctla4 antibodies
CA3131016A1 (en) Multifunctional molecules that bind to calreticulin and uses thereof
AU2015345024A1 (en) Antigen binding molecules comprising a TNF family ligand trimer
CN107614013A (zh) 结合lag‑3的分子和其使用方法
JP2022542559A5 (https=)
WO2022105817A1 (en) Bi-functional molecules
TW202241956A (zh) 新穎抗cd24抗體
US20230416394A1 (en) Novel conjugate molecules targeting cd39 and tgfbeta
JP2021529539A5 (https=)